Novella is an Israel-based startup producing cultured plant-derived nutraceutical ingredients.
Novella’s process begins by selecting the optimal plant tissue from stems, fruits, leaves, and flowers and determining the stage of development for maximum micronutrient concentration. Instead of extraction, the company screens the plant tissues to pinpoint areas with the highest concentration of compounds, then grows the selected cells in a closed, controlled system that stimulates natural propagation. The process also eliminates exposure to pesticides and herbicides common in field-based agriculture. The cells are then converted into a nutritious and bio-accessible powder without the use of solvents.
In October 2023, Novella unveiled prototypes of its new line of cell-cultured berry-derived bioactives and expected to get to market in late 2025 or early 2026. The company also operates a pilot facility for the cultivation of whole-berry fruit cells from five varieties.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.